Life sciences companies rarely have a single hiring model that works for every role. Clinical programs have start and stop dates. Manufacturing ramps are uneven. Leadership gaps appear with little warning. Budget owners want flexibility. Quality and legal teams want continuity and clear accountability.
Contract, contract to hire, and direct hire each solve a different problem. The right choice depends less on preference and more on project length, budget structure, conversion likelihood, and risk. Getting that mix wrong is one of the more common reasons searches drag or new hires leave early.
This framework is meant to help hiring leaders choose the model before the search starts.
What Each Model Is
**Contract** is a time bound engagement. The person is brought in for a defined scope, often tied to a study, submission, tech transfer, validation campaign, or interim coverage. The relationship is expected to end when the work ends, even if both sides are happy with the outcome.
**Contract to hire** starts as a contract with an agreed path to evaluate conversion to permanent employment. It is not a guarantee. It is a structured trial period with conversion criteria, a target window, and usually a conversation about compensation if the conversion happens.
**Direct hire** is a permanent role from day one. The company is hiring for an ongoing need, not a project. Onboarding, benefits, equity, and long term development are part of the package from the start.
All three can work in biotech, pharma, and medical devices. They fail when the model does not match the actual need.
Start With Project Length
Length is the cleanest first filter.
Use **contract** when the work has a foreseeable end. Typical examples include a Phase 2 study that needs extra monitoring support for 9 to 12 months, a CMC writer needed through an IND package, a validation engineer for a specific equipment set, or coverage while someone is on leave. If you can name the end date with reasonable confidence, contract is usually the better fit.
Use contract to hire when the need looks durable but is not yet proven. This is common after a funding round, during a first commercial build, or when a team is testing whether a new function should exist internally. Six to twelve months is a typical evaluation window in life sciences. Shorter windows rarely give enough signal in regulated work.
Use direct hire when the role will still matter 18 to 24 months from now. Core quality leadership, a head of clinical operations, a plant quality lead, or a medical affairs director supporting a launched product usually belong here. If the work is part of the company’s standing operating model, starting on contract often wastes time and weakens the offer.
A simple rule: if the role disappears when the project ends, contract. If the role might become permanent after you see the person in the work, contract to hire. If the role is already part of the org chart for the next planning cycle, direct hire.
Then Look at Budget
Budget structure matters as much as budget size.
Contract spend is usually treated as operating or project expense. That can make approval faster, especially when headcount is frozen. The tradeoff is higher hourly or daily cost and less predictability if the assignment extends.
Contract to hire sits in the middle. Companies often accept a higher short term rate in exchange for the option to convert. The hidden cost is doing the search twice if conversion was never realistic. If finance will not approve a permanent seat later, do not use contract to hire as a workaround. Use contract and be honest about it.
Direct hire carries benefits, bonus, equity, recruiting fees or internal TA cost, and a longer commitment. It is usually the lowest cost per year once the person is productive, but the upfront decision is harder. In small biotechs, equity can make a direct hire more attractive than a high contract rate. In larger pharma, budget cycles and headcount approvals often determine the model before the job description is written.
Ask one practical question: can this role be funded as a permanent seat in the next budget cycle? If no, contract. If maybe, contract to hire. If yes, direct hire.
Conversion Likelihood Should Be Honest
Contract to hire only works when conversion is a real possibility, not a recruiting slogan.
Conversion is more likely when:
– The function is growing, not covering a spike
– Leadership has already discussed a full time seat
– The work requires institutional knowledge that is painful to lose
– The candidate has signaled interest in permanence
– Compensation for conversion has been sketched, even if not finalized
Conversion is unlikely when:
– The program may be partnered, paused, or sold
– Headcount is capped through the next fiscal year
– The need is coverage for a leave or a single submission
– The company has a pattern of ending contracts at the same point every time
Candidates in this market talk to each other. If conversion language is used and then quietly dropped, the next search gets harder. If you are not prepared to convert a strong performer, call it a contract.
Risk Is the Fourth Filter
Risk in life sciences is not only financial. It includes quality, regulatory exposure, knowledge loss, and team stability.
Higher risk for pure contract: roles that own systems, inspections, or long cycle decisions. A quality systems owner, a head of PV, or a manufacturing science lead who holds process knowledge can leave a gap when the assignment ends. Contract still works here for surge support, but the core seat usually needs a permanent owner.
Higher risk for rushing to direct hire: roles where the company does not yet know the scope. Hiring a full time leader into an undefined function is a common source of early exits. Contract to hire reduces that risk if the evaluation criteria are written down.
Higher risk for sloppy contract to hire: unclear conversion terms, no decision date, and no owner for the conversion conversation. That creates candidate drop off and internal friction.
Also consider classification, confidentiality, and training burden. Roles that require deep system access, lengthy GMP training, or representation to agencies often repay the investment of a direct hire. Short, well scoped technical tasks do not.
A Practical Decision Path
Work through the questions in order.
- Does this work have a clear end within 12 months?
If yes, start with contract.
- Will this function still exist after the current program or funding cycle?
If no, stay with contract. If unclear, consider contract to hire.
- Can a permanent seat be approved if the person performs well?
If no, do not use contract to hire.
- Would losing this person after 9 months create quality, inspection, or leadership risk?
If yes, lean toward direct hire or a contract to hire with a firm conversion plan.
- Is speed the binding constraint?
Contract and contract to hire usually start faster than a senior direct hire search. Speed alone is not a reason to avoid permanence if the role is core.
This is not a flowchart that replaces judgment. It is a way to keep the team from arguing about the model after candidates are already in process.
How This Plays Out by Function
Clinical operations and monitoring often fit contract or contract to hire. Studies have phases. Extra CRA or CTM support can be time bound. A head of clinical operations for a company with an ongoing pipeline is usually a direct hire.
Regulatory and quality split. Submission support, gap assessments, and inspection readiness sprints are strong contract uses. System owners, QP style accountability, and heads of quality are better as direct hire or a tightly managed contract to hire.
CMC and manufacturing follow the same split. Campaign support, tech transfer, and CQV execution are frequently contract. MSAT leadership, process ownership, and site quality leadership are usually permanent.
Medical affairs and commercial after a launch often start contract to hire or direct hire. Pre launch medical build can be contract if the asset is still binary.
Executive roles are most often direct hire or fractional first, then direct hire. Contract to hire at VP level is possible but needs unusually clear terms. Senior leaders rarely accept an open ended trial unless the company story and conversion package are specific.